NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Brenig Therapeutics

Brenig Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://brenigtherapeutics.com/

Last Round

Series A

Jul 23, 2024

Total Funding Raised

$73M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Brenig Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative small-molecule therapies for neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Application

Keywords

neurodegenerative disease treatmentParkinson's disease treatmentsmall-molecule therapiesAI drug discoveryLRRK2 inhibitortechbioAI biotechdisease-modifying therapiesbrain-penetrant drugsclinical-stage biotechAI-driven drug designNLRP3 inflammasome inhibitor

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Brenig Therapeutics Comparables

Compare Brenig Therapeutics with similar companies based on industry and business-model similarity.

Brenig Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tenvie Therapeutics
81%
Neuron23
81%
Ventyx Biosciences
80%

Brenig Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 23, 2024
SeedApr 29, 2021

Key People

Founding team and executive leadership

Andrey Sushko

Co-Founder And CTO

Founding Team

Kai Marshland

Co-Founder And Chief Product Officer

Founding Team

Mei-Lan S.

Chief Operating Officer

Executive Team

Brenig Therapeutics Investors

Notable investors and investment history

Brenig Therapeutics investors
InvestorRounds
New Enterprise Associates (NEA)Series A
OrbiMedSeries A, Seed
Torrey Pines Investment LLCSeries A, Seed
i2020 AcceleratorSeed
BioGeneration VenturesSeries A, Seed
BgvcatSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    Grew 15% QoQ, from 78 to 90 employees.

  • Apr 1, 2026

    Balloon constellation quadrupled in size over the past year.

Brenig Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Brenig Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Brenig Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range90
Year Founded2021
Last FundingJul 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.